| Nome |
# |
|
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides, file dd9e0b32-5942-709e-e053-3705fe0a83fd
|
1.400
|
|
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC), file dd9e0b32-6245-709e-e053-3705fe0a83fd
|
1.397
|
|
Biomarkers for the diagnosis and management of heart failure: New frontiers, file dd9e0b32-5cca-709e-e053-3705fe0a83fd
|
724
|
|
Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis, file dd9e0b32-5a78-709e-e053-3705fe0a83fd
|
626
|
|
Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease, file dd9e0b32-630a-709e-e053-3705fe0a83fd
|
532
|
|
Vericiguat for Heart Failure with Reduced Ejection Fraction, file dd9e0b32-6247-709e-e053-3705fe0a83fd
|
296
|
|
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity, file dd9e0b32-6155-709e-e053-3705fe0a83fd
|
252
|
|
Imaging predictors of incident heart failure: a systematic review and meta-analysis, file dd9e0b32-6301-709e-e053-3705fe0a83fd
|
232
|
|
Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors, file dd9e0b32-63b4-709e-e053-3705fe0a83fd
|
227
|
|
Sex-related differences in ventricular remodeling after myocardial infarction, file dd9e0b32-5c1e-709e-e053-3705fe0a83fd
|
188
|
|
Thromboembolism and bleeding in systemic amyloidosis: a review, file dd9e0b32-5c1c-709e-e053-3705fe0a83fd
|
184
|
|
Exercise tolerance and quality of life in patients with known or suspected coronary artery disease, file dd9e0b32-5c20-709e-e053-3705fe0a83fd
|
144
|
|
Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury, file dd9e0b32-633b-709e-e053-3705fe0a83fd
|
143
|
|
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure, file dd9e0b32-633d-709e-e053-3705fe0a83fd
|
143
|
|
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis, file dd9e0b32-620e-709e-e053-3705fe0a83fd
|
124
|
|
Cardiac biomarkers for outcome prediction in infant bronchiolitis: Too soon to discard troponin?, file dd9e0b32-628e-709e-e053-3705fe0a83fd
|
101
|
|
Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology, file dd9e0b32-63f0-709e-e053-3705fe0a83fd
|
93
|
|
RNA-targeting and gene editing therapies for transthyretin amyloidosis, file c6c41c7e-fe0e-49ef-9a83-337fdaad0ef3
|
79
|
|
Longitudinal changes in cardiac biomarkers and outcome in heart failure: Sex-related differences, file dd9e0b32-6307-709e-e053-3705fe0a83fd
|
76
|
|
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis, file dd9e0b32-5945-709e-e053-3705fe0a83fd
|
66
|
|
Myocardial stress perfusion scintigraphy for outcome prediction in patients with severe left ventricular systolic dysfunction, file dd9e0b32-628a-709e-e053-3705fe0a83fd
|
66
|
|
The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population, file 83dd5d23-4e04-4550-a64c-3faf9541b1e0
|
58
|
|
Assessing Cardiac Response to Patisiran by Changes in Extracellular Volume: Potential Issues, file dd9e0b32-62c1-709e-e053-3705fe0a83fd
|
58
|
|
The Relativity of Reference Values for Myocardial Perfusion Imaging, file dd9e0b32-624d-709e-e053-3705fe0a83fd
|
55
|
|
The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals, file dd9e0b32-6153-709e-e053-3705fe0a83fd
|
54
|
|
Biomarkers for the diagnosis and management of heart failure, file dd9e0b32-5ab8-709e-e053-3705fe0a83fd
|
53
|
|
Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis, file 7d579d2a-530c-4c89-8b46-abf05c400a51
|
49
|
|
Non-Vitamin K antagonist oral anticoagulants for mechanical heart valves is the door still open?, file dd9e0b32-5c1d-709e-e053-3705fe0a83fd
|
49
|
|
Aspirin for primary cardiovascular prevention: Is there a need for risk stratification?, file dd9e0b32-63ee-709e-e053-3705fe0a83fd
|
47
|
|
Aspirin for primary cardiovascular prevention: Why the wonder drug should not be precipitously dismissed, file dd9e0b32-63b6-709e-e053-3705fe0a83fd
|
46
|
|
High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis, file 3204f6f5-df7e-4729-8cfd-d7369da3d939
|
45
|
|
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets, file dd9e0b32-6304-709e-e053-3705fe0a83fd
|
44
|
|
Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population, file 4953cbfb-c35b-4092-bf09-6d1fe5ecf40d
|
37
|
|
COVID-19 and myocarditis: a systematic review and overview of current challenges, file dd9e0b32-5a76-709e-e053-3705fe0a83fd
|
36
|
|
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient, file dd9e0b32-6251-709e-e053-3705fe0a83fd
|
35
|
|
Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review, file dd9e0b32-6243-709e-e053-3705fe0a83fd
|
34
|
|
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction, file dd9e0b32-624b-709e-e053-3705fe0a83fd
|
34
|
|
Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook, file e7992fc3-ec84-4b25-9c62-05a7cd865698
|
32
|
|
Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping, file dd9e0b32-5ab9-709e-e053-3705fe0a83fd
|
27
|
|
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is, file 09f33dd1-a8e8-4f1a-8ac5-8f86a88adf65
|
26
|
|
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis, file a7befd8b-ebc8-4830-8f7d-ab4486ddb98d
|
26
|
|
Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification, file dd9e0b32-628c-709e-e053-3705fe0a83fd
|
26
|
|
Myocardial perfusion years after radiation therapy for left-sided breast cancer: Normal or abnormal? This is the question, file dd9e0b32-62c4-709e-e053-3705fe0a83fd
|
23
|
|
Response to the comment by Dr Yarlas, file dd9e0b32-5a74-709e-e053-3705fe0a83fd
|
22
|
|
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism, file 0fc30176-24f9-43bc-85f3-761ec92c7a29
|
15
|
|
Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy, file e15cb778-5187-4d02-8fb5-fcd7ea50a3fb
|
15
|
|
Urinary NGAL in acute heart failure revisited: the game is not over yet, file aa7e39e7-0cbe-4d7b-b685-9115d8186c11
|
14
|
|
Sex-specific associations of myocardial perfusion imaging with outcomes in patients with suspected chronic coronary syndrome, file 032efd50-3172-4547-8fb6-20996408ecb6
|
13
|
|
Prognostic Value of sST2 in Heart Failure, file 20bd1de7-4d0f-45e8-ad03-2b9d94f72e6b
|
11
|
|
Role of Imaging in Cardiomyopathies, file 93b245e0-ef43-43e5-8169-7c35ba1953fc
|
11
|
|
Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation, file 3ee3b87f-50da-4326-9afe-c39441bf5cb5
|
9
|
|
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines, file 47c2a60c-2e52-4e6a-bd2e-ec89cd690308
|
9
|
|
Management of complications of cardiac amyloidosis: 10 questions and answers, file 645f5784-6ac8-44a9-abc4-44da558ccb7b
|
9
|
|
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology, file f8ce3065-0c42-42c2-9395-b4f475ca4598
|
9
|
|
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond, file e8fa6a61-f110-46d2-a8ad-cdccb84a97df
|
8
|
|
Tissue Characterization in Cardiac Amyloidosis, file eae27e6e-da02-4c10-91f4-3ef3f91361d1
|
8
|
|
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction, file 7e02d2be-de52-4fd8-867b-ac1585e4fb25
|
7
|
|
Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology, file d8897332-f8e3-4221-9203-738e5abc2074
|
7
|
|
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis, file f89a8785-44ba-47b8-b703-91a5c2415172
|
7
|
|
Unmet needs in end-of-life care for heart failure patients, file 61cd457f-0ef8-452b-ad5a-cf008ea2ed15
|
6
|
|
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy, file e8fb03c8-508b-4236-8015-5be8d7e9cc33
|
5
|
|
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials, file 19229332-32b1-4cf1-abf6-2a2142d9b30d
|
4
|
|
[Ten perspectives for research and innovation in cardiac amyloidosis], file 389f44e8-88d9-473f-ace3-86a8a581ab13
|
4
|
|
Cardiovascular toxicity from therapies for light chain amyloidosis, file b4a1359b-fe0d-424d-9410-8000f2cf07c1
|
4
|
|
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy, file 089d5f97-187a-405a-8493-ca35d4808bce
|
3
|
|
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin, file 7e6b6d1a-bfc7-4138-9f38-1e3b68f1e79b
|
3
|
|
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter?, file deff2336-6fc6-4484-8eb2-b35b7144764c
|
3
|
|
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond, file e8a3be48-7fc1-4b68-8981-a9bdb4e28283
|
3
|
|
Triglyceride-glucose index predicts outcome in patients with chronic coronary syndrome independently of other risk factors and myocardial ischaemia, file f33d964e-81c8-4951-a82e-154f35076746
|
3
|
|
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis, file faf4aaac-5102-4875-ac70-6b428472bdad
|
3
|
|
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis, file 870d7fcf-2df1-4904-b3e6-bfe157a48fae
|
2
|
|
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review, file 265af18c-a952-415a-9844-df69fc9d4744
|
1
|
|
[Rationale and significance of the Italian Network for Cardiac Amyloidosis], file 7e1cbced-8794-46ca-9776-23cb8be55008
|
1
|
|
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis, file a3d0b9f9-15dc-4e63-b02d-445c1b2b01c7
|
1
|
|
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study, file b4e49d60-b9b1-4cbf-9ce1-1410a2e44ca9
|
1
|
|
Global warming, renal function and heart failure over 20 years, file be961b85-fff8-41ec-97da-33b9854c14d6
|
1
|
|
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction, file f8b28536-e3d8-4920-986e-2616a4d37161
|
1
|
| Totale |
8.210 |